Nasser Youssef, MD
Transplant Surgery · Camden, NJNPI 1063490860
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,958 of the $3,585 with a category attached, or 82.5%. 14 manufacturers reported payments, led by Bard Peripheral Vascular, Inc. at 28.6% of the total. 2025 is the largest year on record at $839, 2.3 times the $371 reported in 2019.
Across 54 payments — averaging $66.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$1K
- Lemaitre Vascular, Inc.$991
- Transmedics, Inc.$534
- Baxter Healthcare$258
- Haemonetics Corporation$196
- Medtronic$158
- plus $420 from 8 others
What the payments were for
- Travel & lodging$62718%
- Food & beverage$2,95882%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bard Peripheral Vascular, Inc. | 26 | $1,027 |
| Lemaitre Vascular, Inc. | 12 | $991 |
| Transmedics, Inc. | 1 | $534 |
| Baxter Healthcare | 3 | $258 |
| Haemonetics Corporation | 2 | $196 |
| Medtronic | 1 | $158 |
| Boston Scientific | 1 | $117 |
| Johnson & Johnson(2 entities) | 2 | $115 |
| Sanofi | 1 | $99 |
| Atricure, Inc. | 1 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Veloxis Pharmaceuticals, Inc. | 1 | $15 |
| Smith+Nephew | 1 | $15 |
| Vifor Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few transplant surgery providers in New Jerseyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 32 | $17,629 |
| Valganciclovir Hcl | 82 | $9,548 |
| Atovaquone | 22 | $7,606 |
| Mycophenolic AcidMycophenolate Sodium | 19 | $3,420 |
| Tacrolimus | 32 | $3,108 |
| Nystatin | 67 | $2,610 |
| Cephalexin | 224 | $789 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 229 | $705 |
| Prednisone | 77 | $581 |
| Labetalol Hcl | 28 | $578 |
| Nifedipine ErNifedipine | 36 | $564 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 99 | $417 |
| Pantoprazole Sodium | 122 | $416 |
| Hydralazine Hcl | 28 | $358 |
| Tamsulosin Hcl | 57 | $215 |
Paid to pharmacies, not to this prescriber.
Other transplant surgery in Camden
- Ely SebastianCamden$2K
- John RadomskiCamden$435
- James GuarreraNewark$1M
- Michael GoldsteinHackensack$158K
- Flavio PaternoNewark$14K
- Caroline RochonCherry Hill$8K
- Arpit AminNewark$5K
- Keri LunsfordNewark$4K
- Ronald PelletierNew Brunswick$3K
- Samuel SultanHackensack$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.